T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SYRS
2551
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $330K | ﹤0.01% |
10,128
+5,220
| +106% | +$211K |
|
2552
AdaptHealth
AHCO
$760M
| $329K | ﹤0.01% |
13,449
-10,738
| -44% | -$252K |
|
|
PFC
2553
DELISTED
Premier Financial Corp. Common Stock
PFC
| $329K | ﹤0.01% |
10,657
-658
| -6% | -$20.7K |
|
2554
Uranium Energy
UEC
$5.54B
| $328K | ﹤0.01% |
98,053
-31,871
| -25% | -$123K |
|
2555
Personalis
PSNL
$1.54B
| $327K | ﹤0.01% |
+22,889
| New | +$382K |
|
|
CBAY
2556
DELISTED
Cymabay Therapeutics
CBAY
| $327K | ﹤0.01% |
96,651
-40,923
| -30% | -$155K |
|
2557
Global Industrial
GIC
$1.49B
| $326K | ﹤0.01% |
7,968
-6
| -0.1% | -$246 |
|
2558
Hooker Furnishings Corp
HOFT
$158M
| $326K | ﹤0.01% |
13,994
+4,800
| +52% | +$121K |
|
2559
Rocky Brands
RCKY
$353M
| $326K | ﹤0.01% |
8,192
+3,500
| +75% | +$151K |
|
|
ACR
2560
ACRES Commercial Realty
ACR
$101M
| $324K | ﹤0.01% |
25,965
| – | – |
|
2561
Fulgent Genetics
FLGT
$513M
| $324K | ﹤0.01% |
3,222
-3,533
| -52% | -$311K |
|
|
FSP
2562
Franklin Street Properties
FSP
$46.4M
| $324K | ﹤0.01% |
54,519
+14,100
| +35% | +$78.8K |
|
2563
Tactile Systems Technology
TCMD
$537M
| $324K | ﹤0.01% |
17,047
+284
| +2% | +$8.05K |
|
2564
Enterprise Financial Services Corp
EFSC
$2.4B
| $323K | ﹤0.01% |
6,850
-585
| -8% | -$27.9K |
|
|
NGM
2565
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $323K | ﹤0.01% |
18,220
-366,496
| -95% | -$7.03M |
|
|
AAIC
2566
DELISTED
Arlington Asset Investment Corp.
AAIC
| $322K | ﹤0.01% |
92,100
-6,800
| -7% | -$25.4K |
|
2567
Atlanticus Holdings
ATLC
$1.47B
| $318K | ﹤0.01% |
+4,455
| New | +$298K |
|
2568
Nuvation Bio
NUVB
$2.14B
| $317K | ﹤0.01% |
37,242
+23,166
| +165% | +$213K |
|
2569
Usana Health Sciences
USNA
$252M
| $317K | ﹤0.01% |
3,131
-650
| -17% | -$64.8K |
|
2570
UWM Holdings
UWMC
$2.61B
| $317K | ﹤0.01% |
+53,551
| New | +$361K |
|
2571
Butterfly Network
BFLY
$2.36B
| $316K | ﹤0.01% |
47,172
+31,878
| +208% | +$280K |
|
2572
WisdomTree
WT
$3.44B
| $316K | ﹤0.01% |
51,631
-2,800
| -5% | -$17.4K |
|
2573
Commercial Vehicle Group
CVGI
$130M
| $314K | ﹤0.01% |
38,931
-4,600
| -11% | -$41.6K |
|
2574
Rocket Companies
RKT
$42.6B
| $314K | ﹤0.01% |
22,432
-17,597
| -44% | -$280K |
|
|
BNFT
2575
DELISTED
Benefitfocus, Inc.
BNFT
| $312K | ﹤0.01% |
29,239
+10,800
| +59% | +$116K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.